Bone marrow neoplastic

Bone marrow neoplastic

Authors: Erika M. Baardsen, D.O., Meenakshi Garg Bansal, M.D., Puneet Bedi, M.D., Marie Calaminici, M.D., Ph.D., Jui Choudhuri, M.D., Genevieve M. Crane, M.D., Ph.D., Courtney D. DiNardo, M.D., Julia T. Geyer, M.D., Benjamin Graham, M.D., Sean Gu, M.D., Ph.D., Rita Gupta, M.D. , Hans Magne Hamnvåg, M.D., Stanley David Hudnall, M.D., Natasha Iranzad, M.D., Hatem Kaseb, M.D., Ph.D., M.P.H., Pallavi Khattar, M.D., Joseph Khoury, M.D., Ameet R. Kini, M.D., Ph.D., Jingwei Li, M.D., Ph.D., Huifei Liu, M.D., Ph.D., Sanam Loghavi, M.D. , Rashmi Manur, M.D., M.P.H., Etan Marks, D.O., Daniela Mihova, M.D., Kamran M. Mirza, M.D., Ph.D., Angeli Mittal, M.D., Monika Nageshwar, M.B.B.S., M.D., Lynh Nguyen, M.D., Oluwatobi "Tobi" Odetola, M.D., Nat Pernick, M.D., Maryam F. Raouf, M.D., Mark Russell, M.D., Valentina Sangiorgio, M.D., Nikhil Sangle, M.D., Vignesh Shanmugam, M.D., Yang Shi, M.D., Ph.D., Alexa J. Siddon, M.D., Zeba N. Singh, M.B.B.S., M.D., Narittee Sukswai, M.D., Lee Bentley Syler, M.D., Zhenya Tang, M.D., Ph.D., Patricia Tsang, M.D., M.B.A., Tayler A. van den Akker, M.D., Endi Wang, M.D., Ph.D., Mariko Yabe, M.D., Ph.D., Sheren Younes, M.D., Syed Zaidi, M.D., Ling Zhang, M.D., Shuchi Zinzuwadia, B.S.

Minor changes: 31 March 2021

Copyright: 2001-2021, PathologyOutlines.com, Inc.

HemePath related: Jobs, Fellowships, Conferences, Cases, CME

Related chapters: Bone marrow nonneoplastic, Hematology, Lymphoma & related disorders, Lymph nodes and spleen, nonlymphoid

Editorial Board oversight: Genevieve M. Crane, M.D., Ph.D. (last reviewed April 2020)

Page views in 2020 (this page and chapter topics): 373,690

Page views in 2021 to date (this page and chapter topics): 117,678

Table of contents

Bone marrow - neoplastic myeloid

General:acute leukemia AML general AML classification books transient abnormal myelopoiesis associated with Down syndrome

Recurrent genetic abnormalities:AML with BCR-ABL1 (pending) AML with biallelic mutation of CEBPA (pending) AML with mutated NPM1 (pending) AML with mutated RUNX1 AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2) aML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22) AML (megakaryoblastic) with t(1;22)(p13.3;q13.1) AML with t(6;9)(p23;q34) AML with t(8;21)(q22;q22) AML with t(9;11)(p22;q23) APL with PML-RARA

AML not otherwise specified:AML with minimal differentiation (FAB AML M0) AML without maturation (FAB AML M1) AML with maturation (FAB AML M2) AMML (FAB AML M4) AML M5 M5a M5b AML M6 AMKL M7 acute basophilic leukemia AML with pseudo-Chediak-Higashi anomaly AML hypocellular

Other AML entities defined by the WHO:myeloid leukemia associated with Down syndrome AML therapy related AML with myelodysplasia related changes myeloid sarcoma acute panmyelosis with myelofibrosis

Other AML of clinical relevance:AML with FLT3

Myelodysplastic syndromes (MDS):WHO classification - MDS MDS prognostic scoring MDS in childhood refractory cytopenia of childhood (pending) MDS with single lineage dysplasia MDS with ring sideroblasts MDS with multilineage dysplasia MDS with excess blasts isolated del(5q) MDS unclassifiable

Myeloproliferative neoplasms (MPN):WHO classification - MPN chronic eosinophilic leukemia chronic myeloid leukemia (CML) chronic neutrophilic leukemia essential thrombocythemia polycythemia vera primary myelofibrosis MPN unclassifiable

Mast cell neoplasms: systemic mastocytosis

MDS / MPN: WHO classification - MDS / MPN atypical chronic myeloid leukemia chronic myelomonocytic leukemia juvenile myelomonocytic leukemia MDS / MPN - unclassifiable MDS / MPN with ring sideroblasts and thrombocytosis

Myeloid / lymphoid neoplasms with eosinophilia and gene rearrangement: PDGFRA rearrangement PDGFRB rearrangement FGFR1 rearrangement PCM1-JAK2

Myeloid neoplasms with germline predisposition without a pre-existing disorder or organ dysfunction:AML with germline CEBPA mutation (pending) with DDX41 mutation (pending)

Myeloid neoplasms with germline predisposition and pre-existing platelet disorders: with RUNX1 mutation (pending) with ANKRD26 mutation (pending) with ETV6 mutation (pending)

Myeloid neoplasms with germline predisposition and other organ dysfunction: with bone marrow failure (pending) with GATA2 mutation with telomere biology disorders (pending) with Down syndrome (pending)

Miscellaneous: blastic plasmacytoid dendritic cell neoplasm hypereosinophilic syndrome

Bone marrow - plasma cell and lymphoid neoplasms

Plasma cell neoplasms:plasma cell neoplasms - General MGUS-IgM MGUS-non IgM plasma cell myeloma (multiple myeloma) non secretory myeloma (pending) plasma cell leukemia (pending) plasmacytoma POEMS syndrome (osteosclerotic myeloma) TEMPI syndrome (pending) heavy chain disease

Other:cryoglobulinemia monoclonal immunoglobulin deposition diseases (pending) primary amyloidosis

B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities:t(1;19)(q23;p13.3) t(5;14)(q31;q32) t(9;22)(q34;q11) t(12;21)(p13;q22) t(v;11q23) BCR-ABL1-like with hyperdiploidy with hypodiploidy with iAMP21 (pending)

NK and T cell precursor lymphoid neoplasms:T lymphoblastic lymphoma / leukemia early T cell precursor lymphoblastic leukemia (pending) NK lymphoblastic leukemia/lymphoma (pending)

Acute leukemia of ambiguous lineage: mixed phenotype ambiguous lineage NOS acute undifferentiated leukemia (pending)

Disorders from other chapters: B lymphoblastic leukemia / lymphoma crystal storing histiocytosis cutaneous mastocytosis heavy chain deposition disease light chain deposition disease

Bone marrow neoplastic stains: CD3 CD34 CD68 CD117 E-cadherin MPO PAX5 TdT

Superpages: entire chapter images virtual slides

Index (Alphabetical table of contents)

A-E:acute basophilic leukemia acute leukemia acute panmyelosis with myelofibrosis acute undifferentiated leukemia (pending) ambiguous lineage NOS AMKL M7 AML (megakaryoblastic) with t(1;22)(p13.3;q13.1) AML classification AML general AML hypocellular AML M5 AML M6 AML therapy related AML with BCR-ABL1 (pending) AML with biallelic mutation of CEBPA (pending) AML with FLT3 AML with germline CEBPA mutation (pending) aML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22) AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2) AML with maturation (FAB AML M2) AML with minimal differentiation (FAB AML M0) AML with mutated NPM1 (pending) AML with mutated RUNX1 AML with myelodysplasia related changes AML with pseudo-Chediak-Higashi anomaly AML with t(6;9)(p23;q34) AML with t(8;21)(q22;q22) AML with t(9;11)(p22;q23) AML without maturation (FAB AML M1) AMML (FAB AML M4) APL with PML-RARA atypical chronic myeloid leukemia BCR-ABL1-like blastic plasmacytoid dendritic cell neoplasm chronic eosinophilic leukemia chronic myeloid leukemia (CML) chronic myelomonocytic leukemia chronic neutrophilic leukemia cryoglobulinemia early T cell precursor lymphoblastic leukemia (pending) essential thrombocythemia

O-Z:PCM1-JAK2 PDGFRA rearrangement PDGFRB rearrangement plasma cell leukemia (pending) plasma cell myeloma (multiple myeloma) plasma cell neoplasms - General plasmacytoma POEMS syndrome (osteosclerotic myeloma) polycythemia vera primary amyloidosis primary myelofibrosis refractory cytopenia of childhood (pending) systemic mastocytosis T lymphoblastic lymphoma / leukemia t(12;21)(p13;q22) t(1;19)(q23;p13.3) t(5;14)(q31;q32) t(9;22)(q34;q11) t(v;11q23) TEMPI syndrome (pending) transient abnormal myelopoiesis associated with Down syndrome WHO classification - MDS WHO classification - MDS / MPN WHO classification - MPN with ANKRD26 mutation (pending) with DDX41 mutation (pending) with ETV6 mutation (pending) with RUNX1 mutation (pending) with bone marrow failure (pending) with Down syndrome (pending) with GATA2 mutation with hyperdiploidy with hypodiploidy with iAMP21 (pending) with telomere biology disorders (pending)

Bone marrow neoplastic books

Cherry: 2021

Hsi: 2017

IARC: 2017

Jaffe: 2016

Kantarjian: 2016

Lanzkowsky: 2016

Naeim: 2018

Find related Pathology books: hematopathology, oncology, pediatric